Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Century Therapeutics (IPSC) over the last 2 years, with Q3 2025 value amounting to $6.8 million.

  • Century Therapeutics' Asset Writedowns and Impairment changed N/A to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 5568.55%. This contributed to the annual value of $16.4 million for FY2023, which is N/A changed from last year.
  • Century Therapeutics' Asset Writedowns and Impairment amounted to $6.8 million in Q3 2025.
  • In the past 5 years, Century Therapeutics' Asset Writedowns and Impairment ranged from a high of $12.1 million in Q4 2023 and a low of $4.2 million during Q2 2023